Serum Soluble Asialoglycoprotein Receptor 1: A Potential Predictor Marker Linked to Type 2 Diabetes Mellitus, Demonstrating Positive Correlation With High Sensitive C-Reactive Protein
Diabetes Metabolic Syndrome and Obesity,
Journal Year:
2025,
Volume and Issue:
Volume 18, P. 663 - 675
Published: Feb. 1, 2025
Asialoglycoprotein
receptor
1
(ASGR1)
deficiency
has
been
implicated
in
enhancing
liver
insulin
sensitivity
and
reducing
systemic
resistance,
thus
highlighting
its
pivotal
role
glucose
metabolism.
However,
the
association
between
serum
soluble
asialoglycoprotein
(sASGR1)
type
2
diabetes
mellitus
(T2DM)
remains
elusive.
Therefore,
we
conducted
a
study
to
delve
into
this
association.
From
July
October
2024,
220
newly
diagnosed
T2DM
patients
an
equal
number
of
matched
controls
with
normal
tolerance
(NGT)
were
enrolled.
Serum
sASGR1
levels
quantified
using
ELISA,
carotid
artery
assessed
ultrasound
imaging.
The
median
level
was
significantly
higher
group
(6.58
ng/mL)
compared
NGT
(5.26
ng/mL).
Notably,
no
significant
difference
observed
individuals
without
atherosclerosis
or
fatty
liver.
In
group,
exhibited
positive
correlation
high-sensitivity
C-reactive
protein
(hs-CRP)
interleukin-6
(IL-6).
Among
patients,
positively
associated
estimated
glomerular
filtration
rate
(eGFR),
resistance
(as
measured
by
HOMA-IR),
triglycerides
(TG),
hs-CRP,
but
negatively
creatinine
(Cr).
linear
regression
analysis
identified
Cr
as
independent
negative
factor
hs-CRP
levels.
Logistic
indicated
that
highest
had
odds
developing
lowest
even
after
adjusting
for
potential
confounders.
significance
attenuated
further
adjustment
hs-CRP.
area
under
receiver
operating
characteristic
(ROC)
curve
0.610.
are
elevated
correlate
demonstrates
limited
predictive
value
onset
T2DM.
Further
research
is
warranted
explore
renal
function,
blood
lipids,
health,
arteriosclerosis.
Language: Английский
A High-Throughput Cell-Based Luciferase Reporter Assay for Identifying Inhibitors of ASGR1
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(10), P. 4590 - 4590
Published: May 10, 2025
The
asialoglycoprotein
receptor
1
(ASGR1)
represents
a
highly
promising
target
for
drug
development,
with
its
expression
regulation
closely
linked
to
various
diseases.
Consequently,
research
concentrating
on
targeted
therapies
against
ASGR1
holds
significant
importance
in
devising
effective
treatment
strategies.
In
this
study,
we
utilized
the
CRISPR-Knockin
technology
insert
firely
luciferase
reporter
gene
downstream
of
exon
9
HepG2
cell
line.
This
modification
enables
level
be
directly
proportional
activity
intensity
protein.
We
successfully
established
screening
and
evaluation
model
employed
it
high-throughput
potential
inhibitors
from
microbial
molecular
metabolite
library.
After
our
process,
several
candidates
were
identified
as
inhibitors.
Western
blotting
experiment
was
conducted
validate
efficacy
model,
thereby
providing
solid
experimental
foundation
development
novel
therapeutics
targeting
ASGR1.
Language: Английский